ReviewBiomedicines2024
Nanoparticle-Based Therapies for Management of Subarachnoid Hemorrhage, Neurotrauma, and Stroke.
Review in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Nanoparticle-Enabled Biomaterials for Controlled Drug Delivery in Implantable and Wearable Devices.International journal of molecular sciences · 2026Review
- The C.O.S.T.A.S. project (Clinically Oriented Spasmolysis Treatment- A Scorescale): a pilot study.Brain & spine · 2026Article
- Endovascular electrocoagulation for treating a blister-like microaneurysm with an extremely narrow neck: A case report.World journal of clinical cases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurotrauma, stroke, and subarachnoid hemorrhage (SAH) are symptomatically diverse and etiologically complex central nervous system pathologies. Despite numerous therapeutic modalities that are available to minimize neurologic damage and secondary injury, the prognosis can still be dismal and unpredictable. Nanoparticle (NP) technology allows for deliberate, modular, and minimally invasive drug delivery. This literature review encompasses pertinent information on the impact and versatility of nanoparticle therapeutics when treating neurotrauma, stroke, and SAH. Currently, notable treatments such as Perfluorooctyl-Bromide (PFOB), PLGA nanoparticles, and ischemic relief-based NPs are promising new techniques for the management of these complex pathologies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.